Article

FDA Says Unapproved Pneumonia Drug Doribax Will Undergo Label Change

Author(s):

After concluding a Doribax (dorpenem) study early, the FDA announced the drug will undergo label changes to reflect increased risk of death for ventilator-associated pneumonia patients.

The Johnson & Johnson drug Doribax (dorpenem) will undergo label changes to warn of an increased risk for death in patients with ventilator-associated pneumonia, the US Food and Drug Administration (FDA) announced.

The new label will reflect findings from a 3-year clinical trial of doripenem in ventilator-associated pneumonia that was terminated early due to safety concerns. “Doribax is not approved to treat any type of pneumonia, and the revised label also includes a new warning about this unapproved use,” the FDA said.

The FDA noted that “Doribax is still considered safe and effective for its FDA-approved indications — treatment of adults with complicated intra-abdominal infections and complicated urinary tract infections, including kidney infections called pyelonephritis.”

In the study, patients with ventilator-associated bacterial pneumonia were either given a 7-day course of doripenem or a 10-day course of imipenem and cilastatin for injection. Clinical cure rates were 11.2% lower in the Doribax arm of the studycompared to patients in the alternative group.

Compared with use of imipenem and silastatin (Merck’s Primaxin), the FDA said doripenem “carries an increased risk of death and lower clinical cure rates.” They also warn that health care professionals should consider whether the benefits outweigh the risks in patients who develop pneumonia while on ventilators.

Related Videos
How Artificial Intelligence is Being Used in Lung Imaging, with Rachel Eddy, PhD
Developing Risk Assessment Tools for Viruses in School
Using Microbiomes to Diagnose Ventilator-Associated Pneumonia
What Do Patients Need to Learn About their Hypersensitivity Pneumonitis?
Discussing Use of Vaping Among Students, Conversations About Vaccines
Pavel Strnad, MD | Credit: RWTH Aachen
Janelle Bludhorn, MS, PA-C: How Common Medications Are Impacted by Extreme Heat
How to Screen for Heat-Related Illness Risks, with Janelle Bludhorn, MS, PA-C
A Promising Pipeline for COPD
© 2024 MJH Life Sciences

All rights reserved.